Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* has a negative clinical history for varicella and herpes zoster~* females of reproductive potential have a negative pregnancy test prior to each study vaccination~* females of reproductive potential remain abstinent or use 2 acceptable methods of birth control during study until 3 months following last study vaccination~* females not of reproductive potential do not require a pregnancy test or use of contraceptives~* legal representative of adult or parent of children understands risks involved with, consent to participate in, and comply with the study procedures~Exclusion Criteria:~* has a history of allergy or anaphylactic reaction to neomycin, gelatin, or any component of VARIVAX\^TM~* has received any form of varicella or herpes zoster vaccine at any time prior to study, or anticipates receiving any during study~* has received immune globulin, a blood transfusion or blood derived products within prior 5 months or plans to do so during study~* has received aspirin or any aspirin-containing products within prior 14 days~* has been exposed to varicella or herpes zoster in the prior 4 weeks involving playmate, hospital or continuous household contact, or had contact with a newborn whose mother had chickenpox 5 days before or 2 days after delivery~* has, or lives with a person who has, any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity including those resulting from corticosteroid use or other immunosuppressive therapy~* has received glucocorticosteroids for more than 5 consecutive days within prior 3 months, or any dose of glucocorticoids within prior 7 days, or expects to use glucocorticosteroids during the study~* was vaccinated with licensed non-live or live vaccine within prior 30 days or expects vaccination during 42 day follow-up postvaccination period~* had a fever within 72 hours prior to study vaccination~* has participated in another trial within prior 30 days, is currently participating in another trial, or plans to participate in another trial during the planned study period for this trial~* is pregnant or nursing

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- VARIVAX™ (Type: EXPERIMENTAL): All participants will receive one dose subcutaneous (SC) VARIVAX™ on Day 1. Adult participants and adolescent participants 13 years and older will also receive a second SC dose VARIVAX™ on Day 43.

Based on this trial design, predict the completion outcome and termination type (if applicable).